Plus Therapeutics highlights promising REYOBIQ data showing safety and survival benefits in brain cancer metastases.

Plus Therapeutics presented positive Phase 1 clinical data for REYOBIQ, a targeted radiotherapy for leptomeningeal metastases, at the 2026 AANS meeting. The data showed improved median survival of about 9 months versus historical 2-6 months, strong tumor reduction, and a favorable safety profile. REYOBIQ also demonstrated precise radiation targeting and potential immune system activation, supporting further trials. Ongoing studies aim to confirm these benefits and explore combination therapies for CNS cancers.